Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: May 22, 2008
Last updated: May 2, 2014
Last verified: May 2014

The purpose of this study is to evaluate the efficacy and safety of single IV doses of Onicit® (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic chemotherapy.

Condition Intervention Phase
Drug: Palonosetron
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication. [ Time Frame: During 24 hours after administration of chemotherapy. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients who achieved a CR and of those who achieved complete control [ Time Frame: Days 1 to 5 at different time intervals for each secondary outcome. ] [ Designated as safety issue: No ]
  • Number of emetic episodes [ Time Frame: Days 1 to 5 at different time intervals for each secondary outcome. ] [ Designated as safety issue: No ]
  • Time to first emetic episode; time to administration and need for rescue therapy; and to treatment failure time to first emetic episode or administration of rescue medication [ Time Frame: Days 1 to 5 at different time intervals for each secondary outcome. ] [ Designated as safety issue: No ]

Enrollment: 59
Study Start Date: April 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Palonosetron
0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
Drug: Palonosetron
0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
Other Name: SCH 734291 - Onicit®


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be 18 years of age or older.
  • Histological or cytological confirmation of malignant disease.
  • Karnofsky index >= 50%
  • Naïve to chemotherapy (First Cycle of chemotherapy IV with moderate or high emetic risk administered during Day 1 of the study, according to modification of the classification of Paul Hesketh's schema published on Annals of Oncology 17: 20-28, 2006 (Appendix 3).
  • Patients that voluntarily sign the consent form.

Exclusion Criteria:

  • Pregnancy or suspected.
  • Patients during breast feeding.
  • Inability to understand or cooperate with the study procedures.
  • Received any investigational drugs within 30 days before study entry.
  • Received any drug with potential anti-emetic efficacy within 24 hours prior to the beginning of the treatment
  • Seizure disorders requiring anticonvulsant medication.
  • Persistent vomiting due to any organic etiology.
  • Experienced any vomiting, nausea or retching, in the 24 hours prior to chemotherapy.
  • Any systemic disease different to base disease
  • Known current or history of drug or alcohol abuse
  • Gastric outlet or intestinal obstruction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00684463     History of Changes
Other Study ID Numbers: P04935
Study First Received: May 22, 2008
Last Updated: May 2, 2014
Health Authority: Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos

Keywords provided by Merck Sharp & Dohme Corp.:

Additional relevant MeSH terms:
Signs and Symptoms
Signs and Symptoms, Digestive
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Serotonin Agents
Serotonin Antagonists processed this record on February 27, 2015